Search
Oxaprozin
go.drugbank.com/drugs/DB00991ApprovedOxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Vidarabine
go.drugbank.com/drugs/DB00194ApprovedWithdrawnIt has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the
Methazolamide
go.drugbank.com/drugs/DB00703ApprovedA carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Pramiracetam
go.drugbank.com/drugs/DB13247ApprovedPramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. … Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470].
Romlusevimab
go.drugbank.com/drugs/DB16494InvestigationalRomlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
Queuine
go.drugbank.com/drugs/DB14732ExperimentalNutraceuticalBacteria possess the exclusive ability to synthesize queuine, which is then salvaged and passed on to plants and animals. … Quantities of queuine have been found in tomatoes, wheat, coconut water, and milk from humans, cows, and goats. Humans salvage and recover queuine from either ingested food or the gut flora.
Progabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated
MN-246
go.drugbank.com/drugs/DB05981ExperimentalMN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.